NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks delivered a negative return of 4.3%, while the Danish biotech stocks fell 4.8%. Acarix secured new orders, Saniona got a new price target with 20% upside, and Ascendis Pharma entered into a USD 150 million funding agreement with Royalty Pharma. Furthermore, the CEOs of Pila Pharma and Acarix bought shares for DKK 150,000-650,000 each.
5 of the 22 Danish biotech companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 288% return and Prostatype Genomics AB was the best Nordic healthcare investment last week. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System (Link)
FILTER-SCAD Study Results Demonstrate Need for Point of Care Rule-Out Options for Coronary Artery Disease in Low-Risk Patients (Link)
The CEO of Acarix bought shares for around DKK 650,000 (Link)
Ascendis Pharma Reports Second Quarter 2024 Financial Results (Link)
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (Link)
No news the past week
No news the past week
CANNORDIC India Ltd., a CS MEDICA Subsidiary, Signs Letter of Intent with the Pharmaceutical Company Zuventus Healthcare to Launch CANNASEN® in India (Link)
CEO Letter: Updates on BSI and Last Months’ Activities (Link)
The Board of Directors resolves on a directed issue of units and preferential rights issue of units (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Major shareholder announcement (Link)
No news the past week
No news the past week
Pila Pharma’s CEP Gustav H. Gram bought shares for around DKK 150,000.
New price target from RedEye was given at SEK 6.
No news the past week
No news the past week
No news the past week
No news the past week
Y-mAbs to Participate in Upcoming Investor Conferences in September (Link)
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research (Link)
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a return of -4.8%. IO Biotech mainly drove the negative return with a 44% decline. This happened following an update of their phase III trial of IO102-IO103 in combination with KEYTRUDA. On the other hand, Acarix and Saniona rose 21-22% each. Acarix got new orders and the CEO also bought shares in the company. Saniona received a price target of SEK 6, while the share is currently trading at SEK 4.99 with a 20% upside to the price target. Ascendis Pharma fell 14% although the company entered into a USD 150 million funding agreement with Royalty Pharma to support continued development and commercialization of endocrine rare disease products including YORVIPATH’s commercial launch in the U.S.
Gubra remains the best-performing stock year-to-date with a return of 288%. Zealand Pharma, Pila Pharma, CS Medica, Y-mAbs Therapeutics have also delivered returns above 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 4.3% to 66,75. The index has had a strong performance since the beginning of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by a couple of percentages.
Development of the KPHC-, C25-, S30- and KPNGX-index for the past year
40-50% in weekly return for the Nordic healthcare stocks
Prostatype Genomics AB (64%) specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. Prostatype Genomics AB’s completed its rights issue during the week and it was subscribed to 79.8 percent including guarantees and debt conversion.
Modus Therapeutics AB (50%) operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company’s focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered.
Biosergen AB (43%) offers a medical device for extracorporeal blood purification. The product removes endotoxin (lipopolysaccharide, LPS) from the patient’s bloodstream, and is applied as an add-on therapy in sepsis to treat endotoxemia (high levels of endotoxin). This can help stabilize the patient in acute situations. Endotoxemia is often present in sepsis, a life-threatening condition and one of the most common causes of death in modern intensive care.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
